September 15, 2015

Company: RIBOMIC Inc.
Address: 3-16-13 Shirokanedai, Minatoku, Tokyo
President & CEO: Yoshikazu Nakamura
(Code: 4591, Tokyo Stock Exchange Mothers)
Inquiries: Masayuki Miyazaki, Board Director (Business Administration)
Phone: +81-3-3440-3303

Announcement of Receipt of Notice of Allowance for Product Patent of Anti-NGF Aptamer (RBM004) by the U.S. Patent Office

We are pleased to announce that we have received from the U.S. Patent Office the Notice of Allowance for product patent of Anti-NGF Aptamer, a joint application by RIBOMIC Inc. and Fujimoto Pharmaceutical Corporation.
This invention covers aptamers that inhibit the action of NGF (Nerve Growth Factor), relevant to the registered Japanese product patent (JP 5027956).

There is no amendment to our financial estimate for the full fiscal year ending March 31, 2016.

<Re: Anti-NGF Aptamer>
This aptamer was created to develop an innovative analgesic medicine by inhibiting NGF, known as a pain mediator.
On April 30, 2014, we executed the License agreement with Fujimoto Pharmaceutical Corporation (Head Office: Matsubara City, Osaka) for granting the worldwide and exclusive right to develop, manufacture and sell this aptamer.